thromboxane-a2 and Rhinitis

thromboxane-a2 has been researched along with Rhinitis* in 2 studies

Other Studies

2 other study(ies) available for thromboxane-a2 and Rhinitis

ArticleYear
Thromboxane A2 Regulates CXCL1 and CXCL8 Chemokine Expression in the Nasal Mucosa-Derived Fibroblasts of Chronic Rhinosinusitis Patients.
    PloS one, 2016, Volume: 11, Issue:6

    Chronic rhinosinusitis without nasal polyps (CRSsNP) is a common chronic disease and the etiology remains unclear. Thromboxane A2 (TXA2) participates in platelet aggregation and tissue inflammation. In this study, the CXCL1/8 chemokine and TXA2-TP receptor expression in the CRSsNP mucosa was investigated.. Immunohistochemistry, chemokine release assay by ELISA, RT-PCR, Real-time PCR, Western blotting, pharmacological and siRNA knockdown analysis were applied in the CRSsNP tissue specimen and cultured nasal mucosa-derived fibroblasts.. The immunohistochemistry results indicated that CXCL1 and CXCL8 were highly expressed in the CRSsNP mucosa compared with the controls; however, the TP receptors were expressed in both mucosa. Therefore, U46619 and IBOP, a TXA2 analog and TP agonist, were used to explore the role of TP activation in CXCL1/8 expression; both of these induced CXCL1/8 mRNA and protein expression in CRSsNP mucosa-derived fibroblasts. U46619 phosphorylated PI-3K, cyclic AMP (cAMP)/PKA, PKC, and cAMP response element (CREB). Activation of cAMP/PKA, PKC, and CREB was the major pathway for cxcl1/8 gene transcription. Pharmacological and siRNA knockdown analyses revealed that activation of cAMP/PKA and PKCĪ¼/PKD pathways were required for CREB phosphorylation and PKA/C crosstalked with the PI-3K pathway.. Our study provides the first evidence for abundant TP receptor and CXCL1/8 expression in human CRSsNP mucosa and for TXA2 stimulation inducing CXCL1/8 expression in nasal fibroblasts primarily through TP receptor, cAMP/PKA, PKCĪ¼/PKD, and CREB-related pathways.

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Bridged Bicyclo Compounds, Heterocyclic; Case-Control Studies; Cells, Cultured; Chemokine CXCL1; Cyclic AMP Response Element-Binding Protein; Fatty Acids, Unsaturated; Fibroblasts; Interleukin-8; Nasal Mucosa; Phosphatidylinositol 3-Kinases; Protein Kinase C; Receptors, Thromboxane A2, Prostaglandin H2; Rhinitis; Second Messenger Systems; Sinusitis; Thromboxane A2

2016
Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats.
    International immunopharmacology, 2007, Volume: 7, Issue:11

    The aim of this study was to investigate the involvement of chemical mediators in a nasal congestion model in Brown Norway (BN) rats. For the above purpose, we studied the effects of pranlukast and zafirlukast (cysteinyl leukotriene (cys-LT) receptor antagonists), seratrodast and ramatroban (thromboxane A(2) (TXA(2)) receptor antagonists) on nasal congestion and sneezing induced by toluene 2, 4-diisocyanate (TDI). All of these drugs suppressed the increase of enhanced pause (Penh), the index of nasal congestion, in both early and late phase responses; however, pranlukast, zafirlukast and seratrodast failed to suppress immediate sneezing caused by TDI challenge. These results indicate that cys-LTs and TXA(2) are responsible for the development of both early and late phase nasal congestion. Moreover, these chemical mediators contribute very little to immediate sneezing in a BN rat model of allergic rhinitis.

    Topics: Animals; Benzoquinones; Carbazoles; Chromones; Dose-Response Relationship, Drug; Heptanoic Acids; Indoles; Leukotrienes; Male; Membrane Proteins; Phenylcarbamates; Rats; Rats, Inbred BN; Receptors, Leukotriene; Receptors, Thromboxane A2, Prostaglandin H2; Rhinitis; Sneezing; Sulfonamides; Thromboxane A2; Tosyl Compounds

2007